TBUFF (MC $23 M)Price 0.48 / 7 Big Drugs launched + Next Approval imminent= TGT $4-6

[Biotechmaster]

Undiscovered Gem with hugh upside Potential

Tribute Pharma (TBUFF)

Market Cap $24 M
Cash $ 3 M

Annual Revenue $13 M and growing
Shares out : 51 M ( 29 M held by Insider and Institutions )


New Presentation


Summary

Canadian Business Includes 7 Marketed Products Including Recently Launched CAMBIA
Tribute sells products in both the primary care and specialty care markets.CAMBIA was launched in October 2012 to compete in the $150 million Canadian migraine market and is expected to be a key contributor to revenue growth in 2013.CAMBIA is a novel, patent-protected, fast-acting, new treatment option for people suffering from acute migraine attacks.Tribute has also entered into a promotional agreement with Pfizer Canada for the exclusive Canadian promotional rights to Gelfoam